Regenerative Medical Technology (RMTG) Income from Discontinued Operations (2022)
Regenerative Medical Technology (RMTG) posted Income from Discontinued Operations of $68663.0 for Q4 2022, up 15920.97% on a QoQ basis from -$434.0 in Q3 2022.
Powered by 
Analysis
Regenerative Medical Technology (RMTG) Income from Discontinued Operations (2022) Analysis & Trends
Regenerative Medical Technology has reported Income from Discontinued Operations for 1 years, with the latest figure at $68663.0 in Q4 2022.
- On a quarterly basis, Income from Discontinued Operations changed N/A year-over-year to $68663.0 in Q4 2022; TTM through Dec 2022 was $68313.0, a N/A change from a year earlier, with the FY2022 full-year figure at $68313.0, up 617.25% from the prior year.
- Income from Discontinued Operations was $68663.0 for Q4 2022 at Regenerative Medical Technology, up from -$434.0 in the prior quarter.
- The five-year high for Income from Discontinued Operations was $68663.0 in Q4 2022, with the low at -$434.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.31 Bn | 9.47 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.67 Bn | 3.37 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.57 Bn | 2.60 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | - |
| 7 | Precigen | 2.36 Bn | 2.36 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.17 Bn | 1.37 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.96 Bn | 1.80 Bn | 56.40 Mn | - |
| 10 | Regenerative Medical Technology | 1.18 Mn | -139,694.93 | 2.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 68,663.00 |
| Sep 30, 2022 | -434.00 |
| Jun 30, 2022 | 208.00 |
| Mar 31, 2022 | -124.00 |